Authors
Amir-Mohammad Asgari, Mohammad Soleimani, Amirhossein Salmannezhad, Aida Orce Rodriguez, Andrew Shimmin, Seyyed Hossein Shafiei, Mohammadreza Golbakhsh
Published in
The archives of bone and joint surgery. Volume 14. Issue 11. Pages 699-710.
Abstract
To systematically review and synthesize available human studies investigating the efficacy and safety of botulinum neurotoxin type A (BoNT/A) injections for managing complications following total knee arthroplasty (TKA) and total hip arthroplasty (THA).
A systematic search of Medline/PubMed, Web of Science, Scopus, and Embase was conducted up to May 2025 per PRISMA 2020 guidelines. Eligible studies enrolled adults who had undergone THA or TKA and received ≥50 units (U) of intra-articular or intramuscular BoNT/A for postoperative pain, stiffness, or musculoskeletal dysfunction. The assessed outcomes included range of motion (ROM), pain scores measured using the Visual Analog Scale (VAS) or Numeric Rating Scale (NRS), functional scores including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Harris Hip Score (HHS), Knee Society Score (KSS), and adverse events.
Thirteen studies met the inclusion criteria, including two RCTs and eleven case studies, with a total of 92 patients. In patients undergoing TKA, BoNT/A was primarily injected into hamstring or gastrocnemius muscles, with doses from 50 to 400 U. Improvements in ROM, KSS, and pain scores were reported in most studies, though statistical significance was inconsistent. In patients undergoing THA, BoNT/A injected into hip adductors, iliopsoas, and tensor fascia lata was associated with reduced flexion contractures and pain, and improved HHS and ODI. No major adverse events were reported; minor effects included bruising and flu-like symptoms.
BoNT/A injections appear to be safe and may be effective for managing chronic pain and flexion contractures following TKA and THA. However, heterogeneity in study design, small sample sizes, limited controls, and variable outcome measures limit the strength of the current evidence. Further high-quality randomized controlled trials are required to establish optimal dosing, timing, injection sites, and to confirm the clinical benefits of BoNT/A in this population.
III.
PMID:
43034824
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0